AstraZeneca Pharma India plans to promote its manufacturing facility in Bengaluru as a part of a strategic evaluate of its international manufacturing and provide community by its mum or dad firm, in accordance with a regulatory submitting.
The corporate stays dedicated to enhancing entry to revolutionary medicines in India, with a transparent ambition to be a frontrunner in science, lead in specialty illness areas, and remodel affected person outcomes, AstraZeneca Pharma India stated in a regulatory submitting on Thursday.
“As a part of AstraZeneca’s ongoing strategic evaluate of its international manufacturing and provide community, the corporate intends to exit its Bangalore manufacturing website, sooner or later,” it added.
The Firm will provide the manufacturing website on the market in a totally operational method and start trying to find a purchaser who may act as a contract manufacturing group (CMO) for its merchandise presently manufactured or packaged on the website, topic to receipt of the mandatory authorized rules. The drug firm stated the approvals.
She added that the corporate is absolutely conscious of the impression that this transformation can have and its first duty might be in direction of its workers and assembly the wants of its sufferers by making certain a steady provide of medicines.
AstraZeneca Pharma India’s Bengaluru facility is considered one of 9 international websites that assist the design and conduct of scientific trials, security and efficacy monitoring, and different regulatory administration required all through the product life cycle.
AstraZeneca Pharma India, a UK subsidiary of AstraZeneca Plc, was based in 1979 and is headquartered in Bengaluru.
(Solely the title and picture of this report could have been reworked by Enterprise Commonplace employees; the remainder of the content material is auto-generated from a syndicated feed.)
First printed: November 16, 2023 | 6:44 pm he
(Tags for translation)AstraZeneca Pharma India
